0.0630USD+0.44%Mkt Cap: —P/E: —Last update: 2026-05-29
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL l…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)43.20M USD
Gross Profit30.74M USD
Net Income (TTM)-10.54M USD
Revenue/Share3.973 USD
Last Price0.0630 USD
Fiscal Year End—
MR Quarter—
Employees84
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.03
EPS (TTM)-1.30
EPS (Forward)—
52W Range
0.022193% of range0.0660
52W High0.0660 USD
52W Low0.0221 USD
Profitability
Gross Margin73.71%
Oper. Margin-38.95%
EBITDA Margin-24.45%
Profit Margin-25.26%
ROE-100.53%
ROA-36.89%
Growth
Revenue Growth17.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.36M USD
CapEx (TTM)2.00K USD
FCF Margin3.42%
FCF Yield—
Net Debt1.40M USD
Net Debt/EBITDA-0.13
Balance Sheet
Debt/Equity0.59
Current Ratio1.21
Quick Ratio0.99
Book Value/Sh0.9000 USD
Cash/Share0.5410 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float8.06M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.91
S&P 52W Chg27.94%
Avg Vol (30d)452
Avg Vol (10d)—
Technical Indicators
RSI (14)33.6
MACD-0.0084
MACD Signal-0.0039
MACD Hist.-0.0045
BB Upper0.0876 USD
BB Middle0.0551 USD
BB Lower0.0225 USD
BB Width118.16%
ATR (14)0.0072 USD
Vol Ratio (20d)56.04x